重庆金域医学

KingMed Diagnostics [Stock Code: 603882] is a high-tech service enterprise centered on third-party medical testing and pathological diagnosis, dedicated to providing leading integrated medical diagnostic information services to medical institutions at all levels across the country. The core entrepreneurial team of KingMed Diagnostics has been actively exploring the operating model of medical testing outsourcing services in China since the 1990s, pioneering the domestic third-party medical testing industry. After years of development, it has now become a market-leading enterprise in the domestic third-party medical testing industry. Currently, KingMed Diagnostics has established 37 central medical laboratories in the mainland and Hong Kong, with a nationwide remote pathology collaboration network, providing accurate, timely, and convenient medical testing and pathological diagnosis services to over 23,000 medical institutions, with a service network covering areas where over 90% of the national population resides. KingMed Diagnostics can provide over 2,700 testing items, with an annual specimen testing volume exceeding 70 million cases, accumulating a large-sample, big-data database of Oriental populations, and based on this, promoting original innovation in the in vitro diagnostic industry and artificial intelligence diagnosis. It has successively won honors such as "Top 10 Most Investment-Worthy Enterprises in China's Healthcare Industry," "21 Future Stars - China's Most Growth-Potential Emerging Enterprises," and Forbes "China Potential Enterprises," and has been approved to establish the National-Local Joint Engineering Laboratory for Medical Testing Technology and Services, the National Genetic Testing Technology Application Demonstration Center, a postdoctoral scientific research workstation, and an academician workstation.